Review suggests TWEAK-Fn14 axis contributes to brain injury and cardiac dysfunction pathology

A systematic review article examined the role of the TWEAK-Fn14 signaling axis in cardio-cerebrovascular diseases and brain-heart syndrome. The review summarized existing preclinical and mechanistic evidence but did not present new data. Details on the study population, sample size, specific interventions, comparators, and follow-up duration were not reported.

The main findings indicate that TWEAK and its receptor Fn14 are overexpressed in cerebral injury. Elevated levels are associated with blood-brain barrier damage, brain edema, neuroinflammation, neuronal apoptosis, and neurodegeneration. In heart diseases, the TWEAK-Fn14 axis is implicated in cardiomyocyte proliferation, inflammation, apoptosis, hypertrophy, fibrosis, contractile function disruption, and ventricular dilatation. No specific effect sizes, absolute numbers, or statistical measures were provided for these associations.

Safety and tolerability data were not reported. The authors note the axis has emerged as a promising therapeutic target for brain-heart syndrome, potentially informing co-treatment strategies. Key limitations include the nature of the evidence, which is a summary of existing literature without new clinical trial data. The review reports associations; causation is not established. The practice relevance is restrained to highlighting a potential mechanistic pathway for future research, not current clinical application.